In a tour-de-force study by Zhang et al.recently published in Nature Metabolism,a newly identified aldolase inhibitor,Aldometanib,is shown to activate lysosomal AMP-activated protein kinase(AMPK).Remarkably,mice treat...In a tour-de-force study by Zhang et al.recently published in Nature Metabolism,a newly identified aldolase inhibitor,Aldometanib,is shown to activate lysosomal AMP-activated protein kinase(AMPK).Remarkably,mice treated with Aldometanib have increased insulin sensitivity,lowered blood glucose,and decreased hepatic steatosis and fibrosis,and are long-lived,effects of which all appear to be mediated via activation of lysosomal AMPK.AMPK is a central regulator of mammalian energy homeostasis,and activation of AMPK regulates a wide range of biological processes that are linked to multiple health benefits,associated with an increased healthy lifespan[1].Designing efficacious AMPK activators for clinical use that show long-term safety profiles has proved challenging,but the potential reward for such drugs would be substantial.展开更多
文摘In a tour-de-force study by Zhang et al.recently published in Nature Metabolism,a newly identified aldolase inhibitor,Aldometanib,is shown to activate lysosomal AMP-activated protein kinase(AMPK).Remarkably,mice treated with Aldometanib have increased insulin sensitivity,lowered blood glucose,and decreased hepatic steatosis and fibrosis,and are long-lived,effects of which all appear to be mediated via activation of lysosomal AMPK.AMPK is a central regulator of mammalian energy homeostasis,and activation of AMPK regulates a wide range of biological processes that are linked to multiple health benefits,associated with an increased healthy lifespan[1].Designing efficacious AMPK activators for clinical use that show long-term safety profiles has proved challenging,but the potential reward for such drugs would be substantial.
